Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4107225 | 1.00 | FAAH (0.35) | FAAHCA2APLNR | |
| SCHEMBL5903659 | 1.00 | FAAH (0.35) | FAAHCA2APLNR | |
| SCHEMBL18110382 | 1.00 | FAAH (0.35) | FAAHCA2APLNR | |
| SCHEMBL2263006 | 0.96 | APLNR (0.32) | FAAHAPLNR | |
| SCHEMBL1164326 | 0.88 | APLNR (0.32) | APLNR | |
| SCHEMBL7103444 | 0.87 | ALDH1A1 (0.36) | CA2APLNR | |
| SCHEMBL7097668 | 0.87 | ALDH1A1 (0.36) | CA2APLNR | |
| SCHEMBL7104975 | 0.87 | ALDH1A1 (0.36) | CA2APLNR | |
| SCHEMBL7103218 | 0.87 | ALDH1A1 (0.36) | CA2APLNR | |
| SCHEMBL7102079 | 0.87 | ALDH1A1 (0.36) | CA2APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376543-A1 | HYALURONIC ACID-COLLAGEN COPOLYMER COMPOSITIONS AND MEDICAL APPLICATIONS THEREOF | SHANGHAI QISHENG BIOLOGICAL PREPARATION CO LTD (CN) | 2025-12-11 | — | — | US | disclosed |
| US-12304974-B2 | Hyaluronic acid-collagen copolymer compositions and medical applications thereof | SHANGHAI QISHENG BIOLOGICAL PREPARATION CO., LTD. (CN) | 2025-05-20 | — | — | US | disclosed |
| WO-2024163315-A2 | DERIVATIZED COLLAGEN-HYALURONIC ACID BASED IMPLANTS FOR SUSTAINED DELIVERY OF OPHTHALMIC DRUGS | DEVORE DALE (US) | 2024-08-08 | — | — | WO | disclosed |
| US-20240252446-A1 | DERIVATIZED COLLAGEN-HYALURONIC ACID BASED IMPLANTS FOR SUSTAINED DELIVERY OF OPHTHALMIC DRUGS | SUSTAINED DRUG DELIVERY LLC | 2024-08-01 | — | — | US | disclosed |
| US-20230203207-A1 | HYALURONIC ACID-COLLAGEN COPOLYMER COMPOSITIONS AND MEDICAL APPLICATIONS THEREOF | SHANGHAI QISHENG BIOLOGICAL PREPARATION CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-7153925-B2 | Condensation polymers from N, N*-disubstituted disulfonamides | PEWS R GARTH | 2006-12-26 | — | — | US | disclosed |
| US-20060128924-A1 | Novel condensation polymers from N, N*-disubstituted disulfonamides | PEWS R G | 2006-06-15 | — | — | US | disclosed |
| US-20030044845-A1 | Novel therapeutic agents for membrane transporters | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-03-06 | — | — | US | disclosed |
| WO-1999064045-A9 | NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS | ADVANCED MEDICINE INC (US) | 2001-07-05 | — | — | WO | disclosed |
| EP-1089749-A1 | NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS | Advanced Medicine, Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-1086063-A4 | NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES | ADVANCED MEDICINE INC (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064050-A9 | NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES | ADVANCED MEDICINE INC (US) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999064045-A1 | NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064050-A1 | NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| US-5670493-A | ANGIOGENESIS INHIBITORS | ADIR ET COMPAGNIE (FR) | 1997-09-23 | — | — | US | disclosed |
| EP-0214853-B1 | Viscoelastic collagen solution for ophthalmic use and method of preparation | MINNESOTA MINING & MFG (US) | 1994-11-30 | — | — | EP | disclosed |
| US-4883864-A | COUPLED AND FREE AMINE GROUPS CAPPED WITH UREA OR AMIDE GROUPS, EYE SURGERY | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1989-11-28 | — | — | US | disclosed |
| US-4851513-A | Viscoelastic collagen solution for opthalmic use and method of preparation | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1989-07-25 | — | — | US | disclosed |
| US-4713446-A | COLLAGEN COUPLED TO CARBONYL OR SULFONYL GROUPS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1987-12-15 | — | — | US | disclosed |
| EP-0214853-A2 | Viscoelastic collagen solution for ophthalmic use and method of preparation | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1987-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030044845-A1 | Novel therapeutic agents for membrane transporters | SLC47A2, SLC8B1, SLC47A1 | FAAH 2264/4885CA2 676/4885APLNR 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.